Quoin Pharmaceuticals Ltd. filed a Form 8-K with the SEC on September 22, 2026, disclosing that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational product candidate QRX003 for the treatment of Peeling Skin Syndrome.
Key Highlights
- FDA Fast Track Designation granted: The FDA awarded Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome, according to the filing.
- Second designation for QRX003: The filing states this is the second Fast Track Designation granted to QRX003, following a previously granted designation for the treatment of Netherton Syndrome.
- Lead asset: The filing describes QRX003 as the company's "lead asset."
- Clinical study goal: The company disclosed it believes the designation will allow it to work closely with the FDA to advance "the first company-sponsored clinical study in this disease."
- Signed by CEO: The report was signed by Dr. Michael Myers, Chief Executive Officer, on September 22, 2026.
FDA Fast Track Designation Awarded to Quoin's QRX003 for Peeling Skin Syndrome
On September 22, 2026, Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) announced via an 8-K current report that the FDA has granted Fast Track Designation to QRX003, an investigational product candidate, for the treatment of Peeling Skin Syndrome. The disclosure was made under both Item 7.01 (Regulation FD) and Item 8.01 (Other Events), with an accompanying press release attached as Exhibit 99.1.
According to the filing, this marks the second Fast Track Designation received for QRX003. The first was granted for the treatment of Netherton Syndrome. The company disclosed its belief that the new designation "will allow it to work closely with the FDA to advance the first company-sponsored clinical study in this disease," referring to Peeling Skin Syndrome.
The filing noted that the information furnished under Item 7.01 and the attached press release "shall not be deemed to be 'filed' with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934," and is not subject to the liabilities of that section unless expressly incorporated by specific reference in another filing. Quoin Pharmaceuticals Ltd. is incorporated in the State of Israel and lists its American Depositary Shares on the Nasdaq Stock Market LLC under the trading symbol QNRX, with each ADS representing thirty-five ordinary shares of no par value per share.
What Was Disclosed
Quoin Pharmaceuticals reported in an 8-K filed September 22, 2026, that the FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome, the second such designation for this candidate following a prior grant for Netherton Syndrome.



Please wait processing your request...